New drug trial aims to shield transplant patients from deadly fungal infections
NCT ID NCT06774144
Summary
This study is testing whether a new antifungal drug called rezafungin can prevent serious fungal infections in liver transplant patients who are at high risk. About 385 patients will receive either rezafungin or standard antifungal medications, and researchers will compare infection rates. The goal is to see if this new option provides better protection against dangerous infections during the critical recovery period after transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.